Share class: Concord Biotech Limited

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A110,46,16,2042,87,87,766 ( 27.52 %) 0 27.52 %

Major shareholders: Concord Biotech Limited

NameStocks%Valuation
28.84 %
3,01,69,524 28.84 % 333 M ₹
9.547 %
99,87,636 9.547 % 110 M ₹
Aryavir Jhunjhunwala Discretionary Trust
8.029 %
83,99,754 8.029 % 93 M ₹
Aryaman Jhunjhunwala Discretionary Trust
8.029 %
83,99,754 8.029 % 93 M ₹
Nishtha Jhunjhunwala Discretionary Trust
8.029 %
83,99,732 8.029 % 93 M ₹
Sudman Consultants LLP
4.542 %
47,52,000 4.542 % 52 M ₹
1575773 Ontario, Inc.
2 %
20,92,325 2 % 23 M ₹
1.934 %
20,23,219 1.934 % 22 M ₹
DSP Asset Managers Pvt. Ltd.
1.748 %
18,28,764 1.748 % 20 M ₹
1.201 %
12,56,432 1.201 % 14 M ₹
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Individuals42.6%
Others31.74%
Institutional4.85%
Unknown20.81%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals
42.6%
India
34.57%
United States
2%
United Arab Emirates
0.01%

Based on 1000 largest holdings

Logo Concord Biotech Limited
Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.
Employees
1,571